Infcare Needle Syringe Program (Infcare NSP), A Database for following and Reducing Injection Risk Behavior Over Time in PWID in Stockholm


Author: Kåberg M, Hammarberg A, Weiland O

Theme: Epidemiology & Public Health Research Year: 2016

INFCARE NEEDLE SYRINGE PROGRAM (InfCare NSP), A DATABASE FOR FOLLOWING AND REDUCING INJECTION RISKBEHAVIOR OVER TIME IN PWID IN STOCKHOLM

Kåberg M1, Hammarberg A1, Weiland O1

1 Karolinska Institutet Department of Medicine Huddinge Sweden

1 Karolinska Institutet Department of Clinical Neuroscience Stockholm Sweden

Background: The first needle syringe program (NSP) was introduced in Stockholm in 2013. Simultaneously, the database InfCare NSP was introduced which is also a clinical decision support tool for collecting and presenting data on participants’ injection risk behavior, HIV- and hepatitis status and vaccination status over time. Data are displayed in a graph on both individual and group level. Since the introduction of InfCare NSP in Stockholm, 3 out of totally 6 NSPs in Sweden have implemented InfCare NSP with a future aim to cover the whole nation and achieve status of National Quality Register.

Results: Among the first 1504 patients enrolled in the Stockholm NSP the prevalence of HIV, hepatitis C and hepatitis B was 6.7%, 82.2% and 2.1% respectively. The overall HCV RNA-positive level was 62.1%. 552 of these patients were enrolled in a more extensive analysis were injection risk behavior was analyzed over time. The results showed significantly decreased risk behavior over a 12-24 month period (p<0.000). Subgroups with the highest risk behavior (females, amphetamine users and homeless) showed the highest level of risk reduction score, 3.79 – 1.7 (p<0.05), 3.27 -1.97 (p<0.05) and 3.84 - 2.5 (p<0.05) respectively. Discussion: The graphic presentation of data registered in InfCare NSP gives an overview of actual risk behavior and serology status which facilitates interaction with patients with the intention to reduce risk behavior to achieve a reduction of HIV- and hepatitis C incidence over time. Disclosure of Interest: Kåberg M, has no conflict of interest. Hammarberg A, has no conflict of interest. Weiland O, has no conflict of interest.

Download poster